Organization (Hospital)
Hallym University Medical Center
ClinicalTrials.gov lists Hallym University Medical Center as lead sponsor of 89 trials, counting the companies grouped under it. Hallym University Medical Center itself has 4 active development programs and 19 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Hallym University Medical Center and 2 companies grouped under it: 89 lead-sponsored trials (53 its own, 36 in the grouped companies) and 3 legal-entity registrations (1 its own, 2 in the grouped companies).
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Companies grouped under this page (2)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Hallym University Kangnam Sacred Heart Hospital | 34 | 1 |
| Hallym University Dongtan Sacred Heart Hospital | 2 | 1 |
Disease areas (160)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Stomach Neoplasms | 15 |
| Rotator Cuff Injuries | 8 |
| Fatty Liver | 6 |
| Fibrosis | 6 |
| Diabetes Mellitus | 5 |
Showing 5 of 160 disease areas.
Trials by start year as sponsor or collaborator (25)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 2 |
| 2023 | 6 |
| 2022 | 1 |
| 2021 | 3 |
| 2020 | 2 |
| 2019 | 5 |
| 2018 | 6 |
| 2017 | 7 |
Showing 10 of 25 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (4)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| OXALIPLATIN | Stomach Neoplasms | Phase 3 | 1 |
| "Capecitabine" | Stomach Neoplasms | Phase 3 | 1 |
| Darbepoetin Alfa Injection | Anemia | Phase 3 | 1 |
| Ferric Derisomaltose Injection | Anemia | Phase 3 | 1 |
Approved assets (19)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| VALSARTAN | 1 |
| enoxaparin only | 1 |
| Rosuvastatin 20mg/d for 14days | 1 |
| High dose Atorvastatin+enoxaparin | 1 |
| (Arm Closed) Enoxaparin | 1 |
Showing 5 of 19 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 0 of 2 hit target (n=2) | 0 of 1 on time (n=1) |
Journals published in (192)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Anesthesiology | 9 |
| Anesthesia and analgesia | 8 |
| Journal of shoulder and elbow surgery | 8 |
| Gastrointestinal endoscopy | 7 |
| The New England journal of medicine | 7 |
Showing 5 of 192 journals.
Organization relationships (32)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Kyunghee University Medical Center | Co sponsors trial with | 7 |
| The Catholic University of Korea | Co sponsors trial with | 5 |
| Soonchunhyang University Hospital | Co sponsors trial with | 5 |
| Ajou University School of Medicine | Co sponsors trial with | 4 |
| Yeungnam University Hospital | Co sponsors trial with | 4 |
Showing 5 of 32 relationships.
Latest dated events (210)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08-17 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-26 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 210 events.
Biomarker capability evidence (145)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| APOB | Trial sponsor | Named in trial inclusion criteria |
| APOH | Trial collaborator | Named in trial inclusion criteria |
| CD274 | Trial collaborator | Named in trial inclusion criteria |
| CIT | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 145 evidence rows.
Biomarkers this organization publishes on (210)
Shown in this order: most publications first.
Showing 5 of 210 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.